Novozymes VELTIS half-life extension technology used by GSK in type 2 diabetes drug

Proprietary Novozymes technology, used in Eperzan product, enables patients to reduce down to once-weekly treatment for diabetes patients

Jeffrey Bouley
COPENHAGEN, Denmark—Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.
 
The application of Novozymes’ VELTIS technology in the drug delivers an extended half-life which will enable patients to inject only once per week.
 
"The first approval for a product based on Novozymes' VELTIS technology, and marketed by one of the largest pharmaceutical companies in the world,  marks a significant milestone for our half-life extension platform", says Thomas Videbæk, Executive Vice President, Business Development, Novozymes. “We consider this authorization real proof that VELTIS can offer true benefits to patients, reducing the inconvenience with daily drug dosing."
 
VELTIS technology is a series of native and engineered human albumins. When combined with a drug candidate, it offers the potential for tunable control of therapeutic half-life in a manner previously unachievable with other half-life extension platforms. In particular, the technology opens the door towards weekly, bi-weekly, or even monthly dosing regimens, a monumental shift away from the daily dosing regimens currently necessary to manage medical conditions.
 
SOURCE: Novozymes

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue